Related references
Note: Only part of the references are listed.The US Food and Drug Administration's use of regular approval for cancer drugs based on single-arm studies: implications for subsequent evidence generation
E. P. DeLoughery et al.
ANNALS OF ONCOLOGY (2018)
Choice of control group in randomised trials of cancer medicine: are we testing trivialities?
Derrick Tao et al.
LANCET ONCOLOGY (2018)
Societal challenges of precision medicine: Bringing order to chaos
Roberto Salgado et al.
EUROPEAN JOURNAL OF CANCER (2017)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Converging on the Value of Value Frameworks
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Genetic Testing: What Problem Are We Trying to Solve?
Kevin S. Hughes
JOURNAL OF CLINICAL ONCOLOGY (2017)
A mission-oriented approach to cancer in Europe: a joint mission/vision 2030
Julio E. Celis et al.
MOLECULAR ONCOLOGY (2017)
Applied Research and Development in Health Care - Time for a Frameshift
Tracy A. Lieu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Evidence for Health Decision Making - Beyond Randomized, Controlled Trials
Thomas R. Frieden
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Randomized, Controlled Trials in Health Insurance Systems
Niteesh K. Choudhry
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Accelerated Approval and Expensive Drugs - A Challenging Combination
Walid F. Gellad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Do cancer drugs improve survival or quality of life? You don't need to know, according to our broken regulatory system
Vinay Prasad
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Do cancer drugs improve survival or quality of life? You don't need to know, according to our broken regulatory system
Vinay Prasad
BMJ-BRITISH MEDICAL JOURNAL (2017)
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Courtney Davis et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms
M. R. Trusheim et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Biomarker Tests for Molecularly Targeted Therapies - The Key to Unlocking Precision Medicine
Gary H. Lyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Limits to Personalized Cancer Medicine
Ian F. Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Integrating Randomized Comparative Effectiveness Research with Patient Care
Louis D. Fiore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pragmatic Trials
Ian Ford et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Real-World Evidence - What Is It and What Can It Tell Us?
Rachel E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Very large treatment effects in randomised trials as an empirical marker to indicate whether subsequent trials are necessary: meta-epidemiological assessment
Myura Nagendran et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey
Lars G. Hemkens et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
Mack Y. Su et al.
PLOS MEDICINE (2016)
Very large treatment effects in randomised trials as an empirical marker to indicate whether subsequent trials are necessary: meta-epidemiological assessment
Myura Nagendran et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey
Lars G. Hemkens et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2015)
Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor
Maria Elena Flacco et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2015)
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
Funda Meric-Bernstam et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Patient-centric trials for therapeutic development in precision oncology
Andrew V. Biankin et al.
NATURE (2015)
A Delicate Balance - Pharmaceutical Innovation and Access
William W. Chin
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Public Health in the Precision-Medicine Era
Ronald Bayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The FDA's new clothes
Donald W. Light et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Why do cancer drugs get such an easy ride?
Donald W. Light et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
The FDA's new clothes
Donald W. Light et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Why do cancer drugs get such an easy ride?
Donald W. Light et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals
Chul Kim et al.
JAMA INTERNAL MEDICINE (2015)
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence
C. M. Booth et al.
BRITISH JOURNAL OF CANCER (2014)
Reducing waste from incomplete or unusable reports of biomedical research
Paul Glasziou et al.
LANCET (2014)
Increasing value and reducing waste: addressing inaccessible research
An-Wen Chan et al.
LANCET (2014)
Increasing value and reducing waste in biomedical research regulation and management
Rustam Al-Shahi Salman et al.
LANCET (2014)
How to increase value and reduce waste when research priorities are set
Iain Chalmers et al.
LANCET (2014)
Increasing value and reducing waste in research design, conduct, and analysis
John P. A. Ioannidis et al.
LANCET (2014)
European perspective for effective cancer drug development
Denis Lacombe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Rapid learning for precision oncology
Jeff Shrager et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?
Susen Burock et al.
EUROPEAN JOURNAL OF CANCER (2013)
Perspective: Transforming Science Into Medicine: How Clinician-Scientists Can Build Bridges Across Research's Valley of Death
Scott F. Roberts et al.
ACADEMIC MEDICINE (2012)
The Emergence of Translational Epidemiology: From Scientific Discovery to Population Health Impact
Muin J. Khoury et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2010)
Share Paper
